[Home ] [Archive]    
:: Home :: About Journal :: Registration :: Article Submission :: Contact us :: Site Map ::
:: Volume 4, Issue 4 (Summer 2012) ::
IJBC 2012, 4(4): 163-168 Back to browse issues page
Detection of Factor VIII Inhibitors in Hemophilia A Patients
Mohsin Sh, Jaffar J, Hussain Sh *, Suhail Sh, Ikram Ullah M, Amjad S
Abstract:   (6908 Views)
Background: Factor VIII administration to hemophilia A patients results in an immune response (inhibitor formation) which significantly complicates the therapy. The present study was performed to determine the prevalence of inhibitor development in hemophilia A patients receiving recombinant factor VIII therapy. Materials and Methods: This was an observational descriptive study. Clotting factor inhibitor screening was performed by activated partial thromboplastin time mixing studies using normal pool plasma collected from twenty healthy donors. Bethesda assay for quantitation of factor VIII inhibitors was performed on samples which were positive with screening tests. Results: Out of 229 patients with hemophilia A enrolled in the hemophilia society of Pakistan, Lahore center, 50 patients were selected. The mean factor VIII level in these patients was 2.46 +3.14. Out of 50 patients, 29 (58%) had severe hemophilia A (factor VIII level <1%), 17 (34%) had moderate hemophilia A (factor VIII level 1-5%) and 4 (12%) had mild hemophilia A (factor VIII level >5-30%). In this study, 12 patients (24%) were positive for inhibitors. Most of them 9 (75%) were low responders (<5 Bethesda units) with a mean Bethesda units of 1.82+0.473, while 3 (25%) patients were high responders (>5 Bethesda units) with a mean BU of 11.33+5.85. Patients were divided into two groups on the basis of the number of factor VIII concentrate therapies of <50 (group 1) times and >50 times (group 2). Inhibitor positivity was high (34.5%) in group I, as compared to group II (9.5%). Bleeding episodes were also more common in inhibitors positive patients. Conclusion: In this study, the inhibitor development in patients with hemophilia A receiving recombinant factor VIII concentrates therapy was 24% and the first fifty therapies were crucial for inhibitor development. Keywords: Hemophilia A, inhibitors, Bethesda units.
Keywords: Keywords: Hemophilia A, inhibitors, Bethesda units.
Full-Text [PDF 727 kb]   (1845 Downloads)    
: Research | Subject: Pediatric Hematology & Oncology
Received: 2012/01/12 | Accepted: 1901/12/14 | Published: 2012/04/16
Add your comments about this article
Your username or Email:

CAPTCHA


XML     Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Sh M, J J, Sh H, Sh S, M I U, S A. Detection of Factor VIII Inhibitors in Hemophilia A Patients. IJBC. 2012; 4 (4) :163-168
URL: http://ijbc.ir/article-1-385-en.html


Volume 4, Issue 4 (Summer 2012) Back to browse issues page
مجله ی خون و سرطان ایران Iranian Journal of Blood and Cancer
Persian site map - English site map - Created in 0.05 seconds with 32 queries by YEKTAWEB 4162